Description: Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Home Page: www.photocure.com
Hoffsveien 4
Oslo,
0275
Norway
Phone:
47 22 06 22 10
Officers
| Name | Title |
|---|---|
| Mr. Daniel Schneider | Pres & CEO |
| Mr. Erik Dahl | Chief Financial Officer |
| Mr. David Moskowitz | Head of Investor Relations |
| Ms. Patricia Kelly | VP of Global HR |
| Dr. Kari Myren M.D. | Head of Global Medical Affairs & Clinical Devel. |
| Dr. Anders Neijber | Chief Medical Officer of Global Medical Affairs, Clinical Devel. and R&D |
| Mr. Tolv Hillestad | Group Controller |
| Mr. Geoffrey Coy | VP and Gen. Mang. of US Operations |
Exchange: OL
Country: NO
Currency: Norwegian Krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 121.9512 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.3304 |
| Price-to-Sales TTM: | 7.7613 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 97 |